- Poster: Exbumin Provides Improved Performance and Stability in Vaccine Development
IPEC-Americas’ 2021 Excipient World Conference may have been postponed, but that doesn’t mean we can’t discuss Excipients!
InVitria, the leader in animal-free, blood-free recombinant proteins and serum-free media, has released a new poster detailing the world’s first rHSA (recombinant Human Serum Albumin) used as an excipient in an FDA- and EMA-approved vaccine. We present and discuss data that demonstrate the superior performance of Exbumin® in virus production and stabilization, including its use in Merck’s ERVEBO® ebola vaccine:
- rHSA is shown consistently to perform better than native forms of albumin and serum products and possesses numerous other supply chain reliability, regulatory, and safety benefits.
- Exbumin enables the realization of the benefits of albumin in production and formulation of vaccines without the variation, safety, and supply chain risks of serum-derived sources.
- Through close partnership, we were able to satisfy the requirements of both FDA and EMA for inclusion as the first rHSA excipient in a human-injectable vaccine.
Exbumin is produced from a non-mammalian expression system, so that it’s consistent, safe, and scalable to your operations. This eliminates serum- and blood-derived components while providing the stabilization and preservation properties of albumin.